Recurrent optic neuromyelitis with endocrinopathies: a new syndrome or just a coincidence?

Petravić, Damir; Habek, Mario; Šupe, Svjetlana; Brinar, Vesna

doi:10.1177/1352458506070756

Cited by 17 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with NMO can be seropositive for acetylcholine receptor (AChR) antibodies and 1–2% have clinical and electrophysiological findings compatible with myasthenia gravis (MG) (class IV) [21,100,101]. Moreover, NMO and NMO spectrum disorders can occur together with endocrinopathies (class IV) [56,102–105].…”

mentioning

confidence: 99%

EFNS guidelines on diagnosis and management of neuromyelitis optica

Sellner

Boggild

Clanet

et al. 2010

Euro J of Neurology

412

353

View full text Add to dashboard Cite

Background and purpose: Neuromyelitis optica (NMO) or Devic¢s disease is a rare inflammatory and demyelinating autoimmune disorder of the central nervous system (CNS) characterized by recurrent attacks of optic neuritis (ON) and longitudinally extensive transverse myelitis (LETM), which is distinct from multiple sclerosis (MS). The guidelines are designed to provide guidance for best clinical practice based on the current state of clinical and scientific knowledge. Search strategy: Evidence for this guideline was collected by searches for original articles, case reports and meta-analyses in the MEDLINE and Cochrane databases. In addition, clinical practice guidelines of professional neurological and rheumatological organizations were studied. In addition, guidance for the work-up and diagnosis of spatially limited NMO spectrum disorders is provided by the task force. Due to lack of studies fulfilling requirement for the highest levels of evidence, the task force suggests concepts for treatment of acute exacerbations and attack prevention based on expert opinion. Conclusions: Studies on diagnosis and management of NMO fulfilling requirements for the highest levels of evidence (class I-III rating) are limited, and diagnostic and therapeutic concepts based on expert opinion and consensus of the task force members were assembled for this guideline. ObjectivesTo provide guidelines for best practice diagnosis and management of adult neuromyelitis optica based on the current state of clinical and scientific knowledge.

show abstract

mentioning

confidence: 99%

EFNS guidelines on diagnosis and management of neuromyelitis optica

Sellner

Boggild

Clanet

et al. 2010

Euro J of Neurology

412

353

View full text Add to dashboard Cite

show abstract

“…18 -20 In conclusion, although NMO is not a common disease in Croatia, severe relapsing types of NMO or other forms of the NMO spectrum including longitudinal extensive transversal myelopathy have been diagnosed on several occasions. 21,22 Taking into account, the poor prognosis of NMO, cases with typical ON with no visual recovery to steroid treatment should raise a suspicion for NMO; therefore, testing for NMO-IgG antibodies is recommended to allow beginning appropriate treatment as soon as possible. The importance of testing for NMO-IgG antibodies in these cases of ON refractory to steroid treatment should be performed further in comparative trials on a larger series.…”

Section: Discussionmentioning

confidence: 99%

Role of NMO-IgG in Distinguishing the Type of Optic Neuritis

Bojić

Kovačić²,

Cerovski³

et al. 2012

Optometry and Vision Science

View full text Add to dashboard Cite

show abstract

“…A rare clinical entity of ‘recurrent neuromyelitis optica with endocrinopathies’ has also been described, largely in a French‐Antillean population, characterised by spinal cord involvement, rapid progression to blindness and an associated endocrinopathy, including a variety of hypothyroidism, galactorrhoea, diabetes insipidus, obesity and diabetes mellitus …”

Section: Discussionmentioning

confidence: 99%

Hypothalamic demyelination causing panhypopituitarism

Dixon-Douglas

Burgess

Dreyer

2018

Internal Medicine Journal

View full text Add to dashboard Cite

Hypothalamic involvement in multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) is rare and endocrinopathies involving the hypothalamic-pituitary axis in patients with demyelinating conditions have rarely been reported. We present two cases of MS/NMOSD with associated hypothalamic-pituitary involvement and subsequent hypopituitarism, including the first report of a patient with hypothalamic demyelination causing panhypopituitarism. Differential diagnoses, including alemtuzumab-related and primary pituitary pathology are discussed.

show abstract

Recurrent optic neuromyelitis with endocrinopathies: a new syndrome or just a coincidence?

Cited by 17 publications

References 9 publications

EFNS guidelines on diagnosis and management of neuromyelitis optica

EFNS guidelines on diagnosis and management of neuromyelitis optica

Role of NMO-IgG in Distinguishing the Type of Optic Neuritis

Hypothalamic demyelination causing panhypopituitarism

Contact Info

Product

Resources

About